Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion type Assertion NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_head.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion evidence source_evidence_literature NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion SIO_000772 14604974 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion wasDerivedFrom befree-20140225 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.
- NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_assertion wasGeneratedBy ECO_0000203 NP699945.RAT7-pU3MElWBCv66gsxu1N91jKWPYyr0q0WQn2WhKr1Q130_provenance.